[1]B. Delahunt, J. C. Cheville, G. Martignoni, P. A. Humphrey, C. Magi-Galluzzi, J. McKenney, L. Egevad, F. Algaba, H. Moch, D. J. Grignon, R. Montironi, J. R. Srigley and T. M. o. t. I. R. T. Panel, The American Journal of Surgical Pathology 2013, 37, 1490-1504.
[2]M. A. Bakitas, Nursing Research 2007, 56, 323-331.
[3]New England Journal of Medicine 2015, 374, 135-145.
[4]K. Yamazaki, M. Sakamoto, T. Ohta, Y. Kanai, M. Ohki and S. Hirohashi, Oncogene 2003, 22, 847-852.
[5]S. R. Prasad, P. A. Humphrey, J. R. Catena, V. R. Narra, J. R. Srigley, A. D. Cortez, N. C. Dalrymple and K. N. Chintapalli, RadioGraphics 2006, 26, 1795-1806.
[6]R. L. Siegel, K. D. Miller and A. Jemal, CA: A Cancer Journal for Clinicians 2017, 67, 7-30.
[7]R. H. Thompson, M. A. Ordonez, A. Iasonos, F. P. Secin, B. Guillonneau, P. Russo and K. Touijer, Journal of Urology 2008, 180, 1262-1266.
[8]E. R. Maher, H. P. H. Neumann and S. Richard, European Journal of Human Genetics 2011, 19, 617-623.
[9]M. L. Nickerson, E. Jaeger, Y. Shi, J. A. Durocher, S. Mahurkar, D. Zaridze, V. Matveev, V. Janout, H. Kollarova, V. Bencko, M. Navratilova, N. Szeszenia-Dabrowska, D. Mates, A. Mukeria, I. Holcatova, L. S. Schmidt, J. R. Toro, S. Karami, R. Hung, G. F. Gerard, W. M. Linehan, M. Merino, B. Zbar, P. Boffetta, P. Brennan, N. Rothman, W.-H. Chow, F. M. Waldman and L. E. Moore, Clinical Cancer Research 2008, 14, 4726-4734.
[10]A. Addeo, R. Bini, T. Viora, L. Bonaccorsi and R. Leli, International Journal of Surgery Case Reports 2013, 4, 648-650.
[11]M. Thompson, Biochimie 2009, 91, 309-319.
[12]J. Brugarolas, The Cancer Journal 2013, 19, 324-332.
[13] P. Kapur, S. Peña-Llopis, A. Christie, L. Zhrebker, A. Pavía-Jiménez, W. K. Rathmell, X.-J. Xie and J. Brugarolas, The Lancet Oncology 2013, 14, 159-167.
[14]Hafez KS, Novick AC, Campbell SC. Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma. J Urol 1997;157:2067–70.
[15]Wunderlich H, Reichelt O, Schumann S, et al. Nephron sparing surgery for renal cell carcinoma 4 cm or less in diameter: indicated or under treated? J Urol 1998;159:1465–9.
[16] Fergany AF, Hafez KS, Novick AC. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol 2000;163:442–5.
[17]Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 1995;22:42–60.
[18] Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 2002;20:2017–24.
[19] Hrushesky WJ, Murphy GP. Current status of the therapy of advanced renal carcinoma. J Surg Oncol 1977;9:277–88.
[20]Bloom HJ. Medroxyprogesterone acetate (Provera) in the treatment of metastatic renal cancer. Br J Cancer 1971;25:250–65.
[21]Weiselberg L, Budman D, Vinciguerra V, Schulman P, Degnan TJ. Tamoxifen in unresectable hypernephroma. A phase II trial and review of the literature. Cancer Clin Trials 1981;4:195–8.
[22] A. Amin, E. R. Plimack, J. R. Infante, M. S. Ernstoff, B. I. Rini, D. F. McDermott, J. J. Knox, S. K. Pal, M. H. Voss, P. Sharma, C. K. Kollmannsberger, D. Y. C. Heng, J. L. Spratlin, Y. Shen, J. F. Kurland, P. Gagnier and H. J. Hammers, Journal of Clinical Oncology 2014, 32, 5010-5010.
[23]B. Rowshanravan, N. Halliday and D. M. Sansom, Blood 2018, 131, 58-67.
[24]J. C. Yang, M. Hughes, U. Kammula, R. Royal, R. M. Sherry, S. L. Topalian, K. B. Suri, C. Levy, T. Allen, S. Mavroukakis, I. Lowy, D. E. White and S. A. Rosenberg, Journal of Immunotherapy 2007, 30, 825-830.
[25] B. I. Rini, M. Stein, P. Shannon, S. Eddy, A. Tyler, J. J. Stephenson Jr, L. Catlett, B. Huang, D. Healey and M. Gordon, Cancer 2011, 117, 758-767.
[26]M. A. Curran, W. Montalvo, H. Yagita and J. P. Allison, Proceedings of the National Academy of Sciences 2010, 107, 4275-4280.
[27]K. E. O'Reilly, F. Rojo, Q.-B. She, D. Solit, G. B. Mills, D. Smith, H. Lane, F. Hofmann, D. J. Hicklin, D. L. Ludwig, J. Baselga and N. Rosen, Cancer Research 2006, 66, 1500-1508.
[28] T. Powles, M. R. Lackner, S. Oudard, B. Escudier, C. Ralph, J. E. Brown, R. E. Hawkins, D. Castellano, B. I. Rini, M. D. Staehler, A. Ravaud, W. Lin, B. O’Keeffe, Y. Wang, S. Lu, J. M. Spoerke, L.-Y. Huw, M. Byrtek, R. Zhu, J. A. Ware and R. J. Motzer, Journal of Clinical Oncology 2016, 34, 1660-1668.
[29] A. Vishwakarma, N. Bocherding, M. S. Chimenti, P. Vishwakarma, K. Nepple, A. Salem, R. W. Jenkins, W. Zhang and Y. Zakharia, bioRxiv 2019, 824482.
[30] Lucas, X.; Van Molle, I.; Ciulli, A. Surface probing by fragmentbased screening and computational methods identifies ligandable pockets on the von Hippel-Lindau (VHL) E3 ubiquitin ligase. J. Med. Chem. 2018, 61 (16), 7387−7393.
[31] S. Biswas and T. Eisen, Nature Reviews Clinical Oncology 2009, 6, 478-487.
[32]B. F. Johnson, T. M. Clay, A. C. Hobeika, H. K. Lyerly and M. A. Morse, Expert Opinion on Biological Therapy 2007, 7, 449-460.
[33]K. M. Mahoney, P. D. Rennert and G. J. Freeman, Nature Reviews Drug Discovery 2015, 14, 561-584.
[34]D. M. Pardoll, Nature Reviews Cancer 2012, 12, 252-264.
[35]Finney R. The value of radiotherapy in the treatment of hypernephroma—a clinical trial. Br J Urol 1973;45:258–69.
[36]Kao GD, Malkowicz SB, Whittington R, D’Amico AV, Wein AJ. Locally advanced renal cell carcinoma: low complication rate and efficacy of postnephrectomy radiation therapy planned with CT. Radiology 1994;193:725–30.
[37]Linehan, W.M., Srinivasan, R., Schmidt, L.S., 2010 May. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 7 (5), 277–285.
[38]J. E. Darnell, Nature Reviews Cancer 2002, 2, 740-749.
[40]P. J. A. Erbel, P. B. Card, O. Karakuzu, R. K. Bruick and K. H. Gardner, Proceedings of the National Academy of Sciences of the United States of America 2003, 100, 15504-15509.
[41] L. M. Greenberger, I. D. Horak, D. Filpula, P. Sapra, M. Westergaard, H. F. Frydenlund, C. Albæk, H. Schrøder and H. Ørum, Molecular Cancer Therapeutics 2008, 7, 3598-3608.
[42]A. Rapisarda, B. Uranchimeg, D. A. Scudiero, M. Selby, E. A. Sausville, R. H. Shoemaker and G. Melillo, Cancer Research 2002, 62, 4316-4324.
[43]J. S. Isaacs, Y.-J. Jung, E. G. Mimnaugh, A. Martinez, F. Cuttitta and L. M. Neckers, Journal of Biological Chemistry 2002, 277, 29936-29944.
[44]B. Onnis, A. Rapisarda and G. Melillo, Journal of Cellular and Molecular Medicine 2009, 13, 2780-2786.
[45]R. Cardoso, R. Love, C. L. Nilsson, S. Bergqvist, D. Nowlin, J. Yan, K. K.-C. Liu, J. Zhu, P. Chen, Y.-L. Deng, H. J. Dyson, M. J. Greig and A. Brooun, Protein Science 2012, 21, 1885-1896.
[46]E. M. Wallace, J. P. Rizzi, G. Han, P. M. Wehn, Z. Cao, X. Du, T. Cheng, R. M. Czerwinski, D. D. Dixon, B. S. Goggin, J. A. Grina, M. M. Halfmann, M. A. Maddie, S. R. Olive, S. T. Schlachter, H. Tan, B. Wang, K. Wang, S. Xie, R. Xu, H. Yang and J. A. Josey, Cancer Research 2016, 76, 5491-5500.
[47]Courtney, K.D., Infante, J.R., Lam, E.T., Figlin, R.A., Rini, B.I., Brugarolas, J., et al., 2016. A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma. J. Clin. Oncol. [Internet] 34, 171054––171176 [cited 2016 Dec 2] (suppl; abstr 2506).
[48]W. Chen, H. Hill, A. Christie, M. S. Kim, E. Holloman, A. Pavia-Jimenez, F. Homayoun, Y. Ma, N. Patel, P. Yell, G. Hao, Q. Yousuf, A. Joyce, I. Pedrosa, H. Geiger, H. Zhang, J. Chang, K. H. Gardner, R. K. Bruick, C. Reeves, T. H. Hwang, K. Courtney, E. Frenkel, X. Sun, N. Zojwalla, T. Wong, J. P. Rizzi, E. M. Wallace, J. A. Josey, Y. Xie, X.-J. Xie, P. Kapur, R. M. McKay and J. Brugarolas, Nature 2016, 539, 112-117.
[49]M. Ruf, H. Moch and P. Schraml, International Journal of Cancer 2016, 139, 396-403.
[50]Olenyuk, B.Z.; Zhang, G. J.; Klco, J. M.; Nickols, N. G.; Kaelin, W.G.; Dervan, P. B. Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc. Natl. Acad. Sci. U. S. A. 2004, 101 (48), 16768−16773.
[51] Higashijima, Y.; Tanaka, T.; Nangaku, M. Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials. Expert Opin. Drug Discovery 2013, 8 (8), 965−976.
[52]Jain, T.; Nikolopoulou, E. A.; Xu, Q.; Qu, A. Hypoxia inducible factor as a therapeutic target for atherosclerosis. Pharmacol. Ther. 2018, 183, 22−33.
[53]Warfel, N. A.; El-Deiry, W. S. HIF-1 signaling in drug resistance to chemotherapy. Curr. Med. Chem. 2014, 21 (26), 3021−3028.
[54]Masoud, G. N.; Li, W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm. Sin. B 2015, 5 (5), 378−389.
[55]Wei, J.; Yang, Y.; Lu, M.; Lei, Y.; Xu, L.; Jiang, Z.; Xu, X.; Guo, X.;Zhang, X.; Sun, H.; You, Q. Recent advances in the discovery of HIF-1alpha-p300/CBP inhibitors as anti-cancer agents. Mini-Rev. Med. Chem. 2018, 18 (4), 296−309.
[56] Li, X.; Cui, X. X.; Chen, Y. J.; Wu, T. T.; Xu, H.; Yin, H.; Wu, Y. C. Therapeutic potential of a prolyl hydroxylase inhibitor FG-4592 for Parkinson’s diseases in vitro and in vivo: regulation of redox biology and mitochondrial function. Front. Aging Neurosci. 2018, 10, 121.
[57]Eltzschig, H. K.; Bratton, D. L.; Colgan, S. P. Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases. Nat. Rev. Drug Discovery 2014, 13 (11), 852−869.
[58]Ema, M.; Taya, S.; Yokotani, N.; Sogawa, K.; Matsuda, Y.; FujiiKuriyama, Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl. Acad. Sci. U. S. A. 1997, 94 (9), 4273−4278.
[59]Gu, Y. Z.; Moran, S. M.; Hogenesch, J. B.; Wartman, L.;Bradfield, C. A. Molecular characterization and chromosomal localization of a third α-class hypoxia inducible factor subunit, HIF3α. Gene Expression 1998, 7 (3), 205−213.
[60]Hoffman, E. C.; Reyes, H.; Chu, F. F.; Sander, F.; Conley, L. H.;Brooks, B. A.; Hankinson, O. Cloning of a factor required for activity of the Ah (dioxin) receptor. Science 1991, 252 (5008), 954−958.
[61]Yamashita, K. D.; Discher, J.; Hu, J.; Bishopric, N. H.; Webster,K. A. Molecular regulation of the endothelin-1 gene by hypoxia.Contributions of hypoxia-inducible factor-1, activator protein-1,GATA-2, and p300/CBP. J. Biol. Chem. 2001, 276 (16), 12645−12653.
[62]Nordgren, I. K.; Tavassoli, A. Targeting tumour angiogenesis with small molecule inhibitors of hypoxia inducible factor. Chem. Soc.Rev. 2011, 40 (8), 4307−4317.
[63]Keith, B.; Johnson, R. S.; Simon, M. C. HIF1α and HIF2α:sibling rivalry in hypoxic tumour growth and progression. Nat. Rev.Cancer 2012, 12 (1), 9−22.
[64]Epstein, A. C.; Gleadle, R. J. M.; McNeill, L. A.; Hewitson, K. S.;O’Rourke, J.; Mole, D. R.; Mukherji, M.; Metzen, E.; Wilson, M. I.;Dhanda, A.; Tian, Y. M.; Masson, N.; Hamilton, D. L.; Jaakkola, P.;Barstead, R.; Hodgkin, J.; Maxwell, P. H.; Pugh, C. W.; Schofield, C. J.;Ratcliffe, P. J. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001, 107 (1), 43−54.
[65] Kamura, T.; Sato, S.; Iwai, K.; Czyzyk-Krzeska, M.; Conaway, R.C.; Conaway, J. W. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl. Acad. Sci. U. S. A. 2000, 97 (19), 10430−10435.
[66] Lando, D.; Peet, D. J.; Whelan, D. A.; Gorman, J. J.; Whitelaw, M.L. Asparagine hydroxylation of the HIF transactivation domain: A hypoxic switch. Science 2002, 295 (5556), 858−861.
[67] Zhu, Y.; Zang, Y.; Zhao, F.; Li, Z.; Zhang, J.; Fang, L.; Li, M.;Xing, L.; Xu, Z.; Yu, J. Inhibition of HIF-1alpha by PX-478 suppresses tumor growth of esophageal squamous cell cancer in vitro and in vivo. Am. J. Cancer Res. 2017, 7 (5), 1198−1212.
[68] Min, J. H.; Yang, H.; Ivan, M.; Gertler, F.; Kaelin, W. G.;Pavletich, N. P. Structure of an HIF-1α-pVHL complex: hydroxyproline recognition in signaling. Science 2002, 296 (5574), 1886−1889.
[69] Hon, W. C.; Wilson, M. I.; Harlos, K.; Claridge, T. D. W.; Schofield, C. J.; Pugh, C. W.; Maxwell, P. H.; Ratcliffe, P. J.; Stuart, D. I.; Jones, E. Y. Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature 2002, 417 (6892), 975−978.
[70] Schofield, C. J.; Ratcliffe, P. J. Signalling hypoxia by HIF hydroxylases. Biochem. Biophys. Res. Commun. 2005, 338 (1), 617−626.
[71] Bruick, R. K.; McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294 (5545), 1337−1340.
[72]Oehme, F.; Ellinghaus, P.; Kolkhof, P.; Smith, T. J.; Ramakrishnan, S.; Hutter, J.; Schramm, M.; Flamme, I. Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors. Biochem. Biophys. Res. Commun. 2002, 296 (2), 343−349.
[73]Metzen, E.; Berchner-Pfannschmidt, U.; Stengel, P.; Marxsen, J.H.; Stolze, I.; Klinger, M.; Huang, W. Q.; Wotzlaw, C.; Hellwig-Burgel, T.; Jelkmann, W.; Acker, H.; Fandrey, J. Intracellular localization of human HIF-1α hydroxylases: Implications for oxygen sensing. J. Cell Sci. 2003, 116 (7), 1319−1326.
[74]Majmundar, A. J.; Wong, W. J.; Simon, M. C. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 2010, 40 (2), 294−309.
[75]Kamura, T.; Koepp, D. M.; Conrad, M. N.; Skowyra, D.; Moreland, R. J.; Iliopoulos, O.; Lane, W. S.; Kaelin, W. G., Jr.; Elledge, S. J.; Conaway, R. C.; Harper, J. W.; Conaway, J. W. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 1999, 284 (5414), 657−661.
[76]Maxwell, P. H.; Wiesener, M. S.; Chang, G.-W.; Clifford, S. C.; Vaux, E. C.; Cockman, M. E.; Wykoff, C. C.; Pugh, C. W.; Maher, E. R.; Ratcliffe, P. J. The tumour suppressor protein VHL targets hypoxiainducible factors for oxygen-dependent proteolysis. Nature 1999, 399, 271.
[77]Brahimi-Horn, M. C.; Pouyssegur, J. Harnessing the hypoxiainducible factor in cancer and ischemic disease. Biochem. Pharmacol. 2007, 73 (3), 450−457.
[78]Willam, C.; Masson, N.; Tian, Y. M.; Mahmood, S. A.; Wilson, M. I.; Bicknell, R.; Eckardt, K. U.; Maxwell, P. H.; Ratcliffe, P. J.; Pugh, C. W. Peptide blockade of HIFalpha degradation modulates cellular metabolism and angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(16), 10423−10428.
[79]Spivak-Kroizman, T. R.; Hostetter, G.; Posner, R.; Aziz, M.; Hu, C.; Demeure, M. J.; Von Hoff, D.; Hingorani, S. R.; Palculict, T. B.; Izzo, J.; Kiriakova, G. M.; Abdelmelek, M.; Bartholomeusz, G.; James, B. P.; Powis, G. Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. Cancer Res. 2013, 73 (11), 3235−3247.
[80]Semenza, G. L. Physiology meets biophysics: visualizing the interaction of hypoxia-inducible factor 1α with p300 and CBP. Proc. Natl. Acad. Sci. U. S. A. 2002, 99 (18), 11570−11572.
修改评论